Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, Sanabria Bohorquez SM, Anania VG, Wildsmith KR, Schauer SP, Lee J, Dolton MJ, Ramakrishnan V, Abramzon D, Teng E; Lauriet investigators. Monteiro C, et al. Among authors: teng e. Neurology. 2023 Oct 3;101(14):e1391-e1401. doi: 10.1212/WNL.0000000000207663. Epub 2023 Aug 29. Neurology. 2023. PMID: 37643887 Free PMC article. Clinical Trial.
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
Jamalian S, Dolton M, Chanu P, Ramakrishnan V, Franco Y, Wildsmith K, Manser P, Teng E, Jin JY, Quartino A, Hsu JC; Alzheimer's Disease Neuroimaging Initiative. Jamalian S, et al. Among authors: teng e. CPT Pharmacometrics Syst Pharmacol. 2023 Jul;12(7):1029-1042. doi: 10.1002/psp4.12974. Epub 2023 May 2. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37101394 Free PMC article.
CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab.
Sandoval C, Lee J, Toth B, Nagaraj R, Schauer SP, Hoffman J, Calderon E, Kollmorgen G, Sanabria Bohórquez SM, Monteiro C, Teng E, Hanson JE, Yeh FL, Gutierrez J, Biever A. Sandoval C, et al. Among authors: teng e. Alzheimers Dement. 2024 Nov;20(11):7940-7953. doi: 10.1002/alz.14271. Epub 2024 Oct 6. Alzheimers Dement. 2024. PMID: 39369294 Free PMC article.
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.
Schauer SP, Toth B, Lee J, Honigberg LA, Ramakrishnan V, Jiang J, Kollmorgen G, Bayfield A, Wild N, Hoffman J, Ceniceros R, Dolton M, Bohórquez SMS, Hoogenraad CC, Wildsmith KR, Teng E, Monteiro C, Anania V, Yeh FL. Schauer SP, et al. Among authors: teng e. Alzheimers Dement. 2024 Dec;20(12):8855-8866. doi: 10.1002/alz.14346. Epub 2024 Nov 8. Alzheimers Dement. 2024. PMID: 39513754 Free PMC article. Clinical Trial.
Automated detection of progressive speech changes in early Alzheimer's disease.
Robin J, Xu M, Balagopalan A, Novikova J, Kahn L, Oday A, Hejrati M, Hashemifar S, Negahdar M, Simpson W, Teng E. Robin J, et al. Among authors: teng e. Alzheimers Dement (Amst). 2023 Jun 22;15(2):e12445. doi: 10.1002/dad2.12445. eCollection 2023 Apr-Jun. Alzheimers Dement (Amst). 2023. PMID: 37361261 Free PMC article.
Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data.
Jo T, Kim J, Bice P, Huynh K, Wang T, Arnold M, Meikle PJ, Giles C, Kaddurah-Daouk R, Saykin AJ, Nho K; Alzheimer's Disease Metabolomics Consortium (ADMC); Alzheimer's Disease Neuroimaging Initiative (ADNI). Jo T, et al. EBioMedicine. 2023 Nov;97:104820. doi: 10.1016/j.ebiom.2023.104820. Epub 2023 Oct 7. EBioMedicine. 2023. PMID: 37806288 Free PMC article.
337 results